Pulsed Shortwave Therapy Adjunct Pain and Recovery in Total Knee Replacement

Total Knee Arthroplasty Clinical Trial

Official title:

Double Blind Placebo-controlled Clinical Trial to Assess Pulsed Shortwave Therapy as an Adjunct Pain Therapy & Knee Recovery for Total Knee Arthroplasty

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03395444
• Other study ID #: Biel-TKA-001
• Status: Recruiting
• Phase: N/A
• Start date: December 15, 2017
• Est. completion date: March 15, 2019

Study information

• Verified date: December 2017
• Source: BioElectronics Corporation
• Contact: Mahmoud Maassarani, Ph.D
• Phone: 96179156547
• Email: M.masarani[@]outlook.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical study is designed to assesses the benefit of adding pulsed shortwave therapy to the postoperative pain and recovery protocol following total knee replacement. Pulsed shortwave therapy is a safe adjunct pain therapy for acute and chronic pain.

Description:

Despite the recent advances in the understanding of pain mechanisms and the introduction of new drugs and new techniques in the postoperative management, pain after total knee arthroplasty (TKA) is still an unresolved issue. It affects the quality of life and rehabilitation of an important percentage of patients undergoing TKA. A recent study looked at the percentage of patients with chronic knee pain after knee replacement at a minimum of one year following surgery in 272 patients, 107 patients (nearly 40%) reported that they still had persistent pain at one-plus year following surgery. Central sensitization is now well established as an integral factor in many chronic pain states, including the commonly occurring knee and back pain. Many patients undergoing TKA are likely to have a significant degree of Central Sensitization, therefore the likely hood of high pain levels postoperative and persistent long standing pain after TKA is increased in this patient population.

Pulsed shortwave therapy negates central sensitization by imputing new

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: March 15, 2019
• Est. primary completion date: December 15, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 80 Years

Eligibility

Inclusion Criteria:

• Meet the diagnostic criteria for knee osteoarthritis;

• Planned spinal anesthesia; American Society of Anesthesiologists (ASA) physical status I-II;

• Scheduled for unilateral TKA;

• Patients aged 50 to 80 years old.

• Willingness to give written informed consent and willingness to participate in and comply with the study.

Exclusion Criteria:

• Unwillingness of the patient;

• Presence of neuropathic pain or sensory disorders in the leg to be operated on;

• Intolerance to the study drugs;

• Failure of spinal anesthesia;

• Previous major knee surgery, re-operation or trauma to the knee within the study period.

Related Conditions & MeSH terms

• Total Knee Arthroplasty

Intervention

Device:
• pulsed shortwave therapy
Pulsed shortwave therapy us the RecoveryRx device. Emits a pulsed signal a the 27.12Mhz wavelength

Locations

Country	Name	City	State
Lebanon	New Mazloum Hospital	Tripoli

Sponsors (1)

Lead Sponsor	Collaborator
BioElectronics Corporation

Country where clinical trial is conducted

Lebanon, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Visual Analogue Pain	The visual analog scale (VAS) has been used extensively for rating pain intensity in previous studies. Postoperative pain at 2, 6, 10, 18, 26, 34, 42, 50, 58, 64, and 72 hours after surgery will be recorded using a 10-cm horizontal line with 1-cm vertical lines at each end labeled "no pain" (left side) and "worst possible pain" (right side). VAS scores will also be recorded also at day 4, 7, 14 and 28 and finally at three months. Different time point assessments are being conducted to look at the change in pain level from baseline through recovery.	Change in pain levels over 3 months
Secondary	The Oxford Knee Score	The Oxford Knee Score (OKS) is a 12-item patient-reported PRO specifically designed and developed to assess function and pain after total knee replacement (TKR) surgery (arthroplasty). It is short, reproducible, valid and sensitive to clinically important changes.	3 months
Secondary	The Knee Injury and Osteoarthritis Outcome Score	The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a knee-specific instrument, developed to assess the patients' opinion about their knee and associated problems. The KOOS evaluates both short-term and long-term consequences of knee injury. It holds 42 items in 5 separately scored subscales; Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related Quality of Life (QOL).	3 months
Secondary	Pain Pressure Threshold	Pain Pressure Threshold, is used routinely in clinical practice to assess pain sensitivity from musculoskeletal pain to indicate the level of pain sensitivity in individuals to central sensitization of the nervous system. Testing will occur locally above the effected knee as well as peripherally on the distal interphalangeal joint.	3 months
Secondary	The Pain and Sleep Questionnaire three-item index	The Pain and Sleep Questionnaire three-item index (PSQ-3): A reliable and valid measure of the impact of pain on sleep in chronic nonmalignant pain of various etiologies.	3 months
Secondary	Active Range of Motion	Active range of motion (A-ROM) is an important component of the assessment of total knee replacement (TKR) outcome. The goal of knee replacement recovery is to achieve flexion of 135 degrees. Range of motion will be measured by observational method by two separate individuals.	3 months
Secondary	Analgesic medication use	Analgesic medication use for the postoperative period of 7 days as well as a further 21 days will be recorded - 28 day total.	28 days